Where Chinook Therapeutics Stands With Analysts
Analysts have provided the following ratings for Chinook Therapeutics (NASDAQ:KDNY) within the last quarter: Bullish Somewhat Bullish Indifferent…
Recap: Chinook Therapeutics Q1 Earnings
Chinook Therapeutics (NASDAQ:KDNY) reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:00 PM. Here’s what…
Chinook Therapeutics Trial Pause: Unfortunate But Analyst Reassures No Damage To Value Drivers
Chinook Therapeutics Inc (NASDAQ:KDNY) has voluntarily paused dosing in the Phase 1 trial of CHK-336 in healthy volunteers to allow a…
Piper Sandler Initiates Coverage On Chinook Therapeutics with Overweight Rating, Announces Price Target of $41
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Chinook Therapeutics (NASDAQ:KDNY) with a Overweight rating and announces Price Target of $41.
Chinook Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Chinook Therapeutics (NASDAQ:KDNY) reported Q4 sales of $512 thousand. Earnings fell to a loss of…
Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside
Guggenheim starts coverage on Chinook Therapeutics Inc (NASDAQ:KDNY) with a Buy rating and a $43 price target, being ‘bullish’ on the immunoglobulin…
Where Chinook Therapeutics Stands With Analysts
Within the last quarter, Chinook Therapeutics (NASDAQ:KDNY) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Have A Look At William Blair’s Top Biotech Picks For 2023
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.
Chinook Therapeutics Presents Updated Data From Atrasentan Phase 2 AFFINITY IgA Nephropathy Patient Cohort, Preclinical Atrasentan Research And Ongoing Clinical Trials At The American Society Of Nephrology Kidney Week 2022
Atrasentan was well-tolerated with no treatment-related serious adverse events (SAEs)
Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at